AngioDynamics (ANGO) Updates FY19 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY19 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus estimate of $0.84. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $356.31 million.

Shares of AngioDynamics stock traded up $0.17 during trading hours on Friday, reaching $19.99. The company’s stock had a trading volume of 272,062 shares, compared to its average volume of 235,188. AngioDynamics has a one year low of $18.11 and a one year high of $25.48. The company has a quick ratio of 1.70, a current ratio of 2.68 and a debt-to-equity ratio of 0.23. The company has a market cap of $744.03 million, a PE ratio of 27.01 and a beta of 0.68.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, April 2nd. The medical instruments supplier reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.03). AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. The firm had revenue of $86.34 million for the quarter, compared to analysts’ expectations of $88.30 million. During the same period in the prior year, the firm posted $0.23 earnings per share. AngioDynamics’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, sell-side analysts expect that AngioDynamics will post 0.83 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on ANGO shares. ValuEngine cut shares of AngioDynamics from a buy rating to a hold rating in a research report on Friday, April 19th. Zacks Investment Research upgraded shares of AngioDynamics from a sell rating to a hold rating in a research note on Wednesday, April 24th. TheStreet lowered shares of AngioDynamics from a b rating to a c+ rating in a research note on Thursday, April 18th. Finally, BidaskClub raised shares of AngioDynamics from a buy rating to a strong-buy rating in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $23.50.

WARNING: This story was published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: Limitations of the P/E Growth ratio

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.